US biotech looks to bolster pipeline.
Tesara and Takeda among other companies to publish data.
Veliparib fails in two phase 3 trials.
Company nabs maintenance therapy use, but problems on breast cancer trial.
UK firm lays down the gauntlet in the PARP inhibitor battle.
UK pharma also gets $130m payment from Valeant.
Clovis’ Rubraca will compete against AstraZeneca rival.
Novocure’s Optune device shown to be safe and tolerable in recurrent ovarian cancer.